Prof.G.Walter Canonica
Allergy and Respiratory Diseases Clinic
DIMI-‐University of Genoa
Italy
Presidente Congreso SLaai 2015: Dr. Alfonso Cepeda Sarabia
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Recent Advances in the Treatment of Childhood Asthma - Robert LemanskeJuan Carlos Ivancevich
Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015
Monomeric allergoid: the new advances of AIT, in only one product. Dr. Enrico...Juan Carlos Ivancevich
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Recent Advances in the Treatment of Childhood Asthma - Robert LemanskeJuan Carlos Ivancevich
Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015
Monomeric allergoid: the new advances of AIT, in only one product. Dr. Enrico...Juan Carlos Ivancevich
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...Juan Carlos Ivancevich
Symposium: Immunotherapy in Latin America - WISC 2014- Rio de Janeiro
Symposium 5: Latin American Society of Allergy and Immunology (SLAAI) Symposium: Immunotherapy in Latin America Sala 1 & 2 (Sul America)
Hypersensitivity reactions to nonsteroidal anti-inflammatory drugsNatacha Santos
Reis-Ferreira A, Santos N, Botelho C, Castro E, Cernadas JR. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: single versus multiple reactors. Allergy 2011;66(Suppl.94):51-52.
Immunotherapy in children SCIT or SLIT. Dra. Desirée Larenas WISC Dec2014 ...Juan Carlos Ivancevich
Symposium: Immunotherapy in Latin America - WISC 2014- Rio de Janeiro
Symposium 5: Latin American Society of Allergy and Immunology (SLAAI) Symposium: Immunotherapy in Latin America Sala 1 & 2 (Sul America)
Hypersensitivity reactions to nonsteroidal anti-inflammatory drugsNatacha Santos
Reis-Ferreira A, Santos N, Botelho C, Castro E, Cernadas JR. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: single versus multiple reactors. Allergy 2011;66(Suppl.94):51-52.
The similarities and differences of the recommendations of azithromycin ther...WAidid
Slideset by Professor Blasi explains when and why using Azithromycin in pneumonia and underlines the importance of combination therapy, that reduces mortality and complications both in children and adults, particularly in moderate-severe pneumonia.
ICN Victoria presents Professor Oliver Cornely, Professor of Internal Medicine and Director for Clinical Trials at University Hospital, Cologne, Germany. His research interests include invasive fungal diseases in haematology/oncology and in the ICU setting. Dr Cornely is also a clinical infectious diseases consultant at the University Hospital of Cologne.
Professor Cornely gives an entertaining talk on the pervasiveness, invasiveness, diagnosis and treatment of fungal infections in ICU patients.
Respond to this discussion . Add some facts with at least 2 cita.docxcwilliam4
Respond to this discussion . Add some facts with at least 2 citations APA Format
Discussion: Community-Acquired Pneumonia
Case Study
HH is a 68-yr M who has been admitted to the medical ward with community-acquired pneumonia for the past three days. His PMH is
significant for COPD, HTN, hyperlipidemia, and diabetes. He remains on empiric antibiotics, including ceftriaxone 1 g IV q day (day 3) and
azithromycin 500 mg IV q day (day 3). Since admission, his clinical status has improved, with decreased oxygen requirements. He is not tolerating a
diet at this time, complaining of nausea and vomiting. Ht: 5'8" Wt: 89 kg Allergies: Penicillin (rash).
Diagnosis: Community-Acquired Pneumonia (CAP)
CAP is the term used to describe an acute infection of the lungs that develops outside the hospital setting by an immune-competent
individual who has not been recently hospitalized (Shoar & Musher, 2020). Adults with CAP typically present with cough, fever, sputum production or
shortness of breath, oxygen desaturation, confusion, leukocytosis or leukopenia, and pleuritic chest pain, along with the presence of an acute
infiltrate on the chest radiograph (Shoar & Musher, 2020).
Antibiotic suggested for CAP's empiric treatment is based on agents useful against CAP's major treatable bacterial causes. The bacterial
pathogens responsible for CAP include Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, Legionella species, and Moraxella catarrhalis (Metlay et al., 2019).
The patient is on right treatment, his clinical status has improved, with decreased oxygen requirement. Recommended treatment plan for
patients with comorbidities such as alcoholism, COPD, post influenza, asplenia, diabetes mellitus, lung/liver/renal diseases include: Combination
of a beta-lactam (ceftriaxone 1 g IV q24h or cefotaxime 1 g IV q8h or ceftaroline 600 mg IV q12h) plus azithromycin 500 mg IV q24h (Donovan, 2019).
The therapy duration is a minimum of 5 days. The patient needs to be afebrile for 48-72 hours, controlled blood pressure, adequate oral intake, and
room air oxygen saturation of greater than 90% and treatment duration can be extended if symptoms are not recovered in some cases (Donovan,
2019).
In this case, the patient symptoms are improving, his oxygen requirement is decreased, but he is not tolerating a diet at this time,
complaining of nausea and vomiting. The patient received antibiotics for three days, so antibiotics need to be continued. With appropriate antibiotic
therapy, some improvement in the patient's clinical course is usually seen within 48 to 72 hours (File, 2020).
Health Needs and Treatment Regimen
The patient is not tolerating diet and complaining of nausea and vom.
Food allergy has been long recognized and well documented. Other adverse reactions to foods first referred to as “toxic idiopathies” by John Freeman, co inventor of immunotherapy, at the early part of the 1900s can be mediated by and have their impact on the nervous and endocrine systems. It can also be mediated by pharmacologic mechanisms and can also affect any part of the body. There’s a great clinical need to accurately identify triggers of adverse reactivity as they have now been linked with even the most serious of modern maladies and diseases. In fact, inflammation is the hallmark of metabolic syndrome. Given the multitude of pathogenic mechanisms underlying adverse reactions to foods and other environmental exposures it is necessary that a utilizable and cost effective technology be understood so that its application be utilized under the appropriate circumstances.
KEY LEARNING POINTS
• The natural ability of certain foods to initiate an inflammatory response and induce metabolic disruptions and counterbalancing mechanisms to prevent that
• How foods can trigger “danger signals” for the immune system
Pharmacologic vs. immunologic reactions to foods
• Is there a common final pathway of all these mechanisms that can reliably indicate triggers of clinical pathology?
• Cellular testing vs. serologic testing: The advantages of cellular testing
A Paradigm Shift in the Utilization of Therapeutic Plasmapheresis in Clinical...semualkaira
Therapeutic Plasma Exchange (TPE), frequently referred to as
plasmapheresis. is an automated procedure which separates whole
blood into plasma and blood cells. The plasma is discarded and
replaced with physiologic fluids and returned to the patient along
with the blood cells. Theoretically, any disease in which a humoral
phase is implicated in the pathogenesis may be at least partially
mitigated by removal of the patient’s plasma and replacement with
physiologic solutions. In clinical practice, TPE is used in a hospital
setting, usually as a last resort, to treat autoimmune diseases by removing circulating antibodies and/or immune complexes. Recently, it was demonstrated that TPE has several immunoregulatory
properties besides removal of circulating antibodies and immune
complexes. Both controlled and uncontrolled clinical studies have
demonstrated that TPE is associated with only a few mild adverse
reactions and can be performed safely in an outpatient setting.
We report our experience in treating patients with TPE on an outpatient basis with several different medical conditions (Alzheimer’s disease, Long Covid, PANDAS) and prophylactically in older
individuals for the attenuation of inflammaging
A Paradigm Shift in the Utilization of Therapeutic Plasmapheresis in Clinical...semualkaira
Therapeutic Plasma Exchange (TPE), frequently referred to as
plasmapheresis. is an automated procedure which separates whole
blood into plasma and blood cells. The plasma is discarded and
replaced with physiologic fluids and returned to the patient along
with the blood cells. Theoretically, any disease in which a humoral
phase is implicated in the pathogenesis may be at least partially
mitigated by removal of the patient’s plasma and replacement with
physiologic solutions
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
The Future of Allergy and Clinical Immunology Prof. G. Walter Canonica - Congreso Slaai 2015
1.
2. Prof.
Giorgio
Walter
Canonica
Allergy
and
Respiratory
Diseases
Clinic
DIMI-‐University
of
Genoa
IRCCS
AOU
San
Mar:no-‐Genova
Italy
President
President
SLAAI, March 15, 2015
The Future of Allergy
and
Clinical Immunology
39. The promise of personalized medicine
• More effective medicines
• Safer medicines
• Cheaper medicines
• Better healthcare
• Cheaper healthcare
• Less (rather than more)
healthcare disparity
42. G551D
is
the
third
most
common
muta:on,
affec@ng
~4%
of
pa@ents.
For
pa:ents
homozygous
for
Δ508,
Vertex
has
another
drug,
VX-‐809,
which
acts
by
increasing
the
transport
of
CFTR
protein
to
the
cell
surface.
A
phase
2
clinical
trial
of
combined
VX-‐809
and
VX-‐770
treatment
in
Δ508
pa:ents
is
in
progress.
Vx-‐770
poten:ates
CFTR
func:on
by
promo:ng
decoupling
between
the
ga:ng
cycle
and
ATP
hydrolysis
cycle.
Jih
KY.
et
al.
PNAS.
2013;
110:
4404-‐9
Vx-‐770;
Ivaca[or
A CFTR potentiator in patients with cystic fibrosis and
the G551D mutation (most
prevalent
ga:ng
muta:on)
Ramsey BW, et al. N Engl J Med. 2011; 3658: 1663-72
Complex disease will be stratified into a series of
pathway specific disorders creating opportunities for
both companion diagnostics and targeted
prevention and treatments.
But also a new Taxonomy of disease based upon causative
pathways rather than signs and symptoms.
43. Crea:on
of
a
New
Taxonomy
first
requires
an
“Informa:on
Commons”
in
which
data
on
large
popula:ons
of
pa:ents
become
broadly
available
for
research
use
and
a
“Knowledge
Network”
that
adds
value
to
these
data
by
highligh:ng
their
inter-‐
connectedness
and
integra:ng
them
with
evolving
knowledge
of
fundamental
biological
processes
Toward
Precision
Medicine.
US
Nat
Acad
Sci
2011
Reclassification of human disease by
identifiable causal pathways
50. ASTHMA HORIZON PLANNING
in the next 5 years
tralokinumab
(an@
IL
13,
MedImmune)
ligelizumab
(an@
IgE,
Novar@s)
dupilumab
(an@
IL
4
rec,Sanofi
Regeron)
55. JACI
2013
ISSN 0091-6749
V O L U M E 1 2 9 N O. 4
A P R I L 2 0 1 2
www.jacionline.org
THE JOURNAL OF
AllergyAND Clinical
Immunology
CURRENT PERSPECTIVES
ICON: Food allergy
The role of dendritic cells in food allergy
ROSTRUM
Multiple-allergen and single-allergen
immunotherapy strategies in polysensitized
patients: Looking at the published evidence
Health literacy and asthma
WORKSHOP SUMMARY
Understanding the complexity of IgE-related
phenotypes from childhood to young
adulthood: A Mechanisms of the Development
of Allergy (MeDALL) Seminar
CLINICAL REVIEWS
An update on the role of human dendritic cells
in patients with atopic dermatitis
MECHANISMS OF ALLERGIC DISEASES
The role of dendritic cells in asthma
EDITORIALS
We call for iCAALL: International Collaboration
in Asthma, Allergy and Immunology
The airway epithelium in childhood asthma
TH
9 cells: In front and beyond TH
2
Nonimmediate drug allergy: Diagnostic benefit
of skin testing and practical approach
OFFICIAL JOURNAL OF
67. Auffray
et
al.
Genome
Med
2009;1:2
PaEent
reported
Clinical
FuncEonal
Cellular
Molecular
Future
of
phenotyping:
‘Systems
Medicine’
68. Prof.
Giorgio
Walter
Canonica
Allergy
and
Respiratory
Diseases
Clinic
DIMI-‐University
of
Genoa
IRCCS
AOU
San
Mar:no-‐Genova
Italy
President
President
SLAAI, March 15, 2015
The Future of Allergy
and
Clinical Immunology
(Part IV - final)
81. 0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
t=p/4
x
arithme2c
mean
of
orthogonal
intercepts
PRE
POST
RESULTS
Riccio,
Dal
Negro
et
al.,Int.J.Immunopathol.
&
Pharmacol.2012
82. 3.00
5.50
8.00
10.50
13.00
BEFORE
AFTER
TREATMENT
t=p/4
x
arithme2c
mean
of
ortogonal
intercept
12 month Xolair treatment
RESULTS
Riccio,
Dal
Negro
et
al.,Int.J.Immunopathol.
&
Pharmacol.2012
RESPONDER
NON
RESPONDER
6.25 µ
Severe
Asthma
Cut
off
95. FINAL
MESSAGE
Bioinforma2cs,
E-‐health
records,
Bio-‐banks
and
data
protec2on
Although
‘omics’
datasets
have
provided
remarkable
insights,
it
is
by
analysing,
linking
and
comparing
different
large
datasets
(genomic,
clinical
outcomes,
imaging
etc.)
that
the
greatest
insights
have
been
gained
–
so-‐
called
‘big
data’.
96. XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015
http://www.slaai2015.com/comites-del-congreso/
Información Slaai: www.slaai.org
Programa Congreso Para Todos
Conferencias XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología
Sociedad Latinoamericana de Alergia, Asma e Inmunología, SLaai